Canaccord lowered the firm’s price target on Zevra Therapeutics (ZVRA) to $24 from $25 and keeps a Buy rating on the shares. The firm lowered its target on a softening Europe Miplyffa ramp.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA: